This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hibberts, N. A. Articles by Farrell, W. E. Search for Related Content PubMed PubMed Citation Articles by Hibberts, N. A. Articles by Farrell, W. E.

Analysis of Cyclin D1 (CCND1) Allelic Imbalance and Overexpression in Sporadic Human Pituitary Tumors¹

Centre for Cell and Molecular Medicine, School of Postgraduate Medicine, Keele University, North Staffordshire Hospital, Stoke on Trent ST4 7QB [N. A. H., D. J. S., J. E. B., P. R. H., R. N. C., W. E. F.], and Department of Neuropathology, Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool L9 7LJ [J. C. B.], United Kingdom

Cyclin D1 plays an important role in the regulation of cell progression through G₁ of the cell cycle and has been demonstrated to have oncogenic properties. Using RFLP-PCR, an A/G polymorphism within the cyclin D1 (CCND1) gene was analyzed in 151 sporadic human pituitary tumors, of which 60 were informative at this locus. Further analysis showed that in 15 of 60 (25%) tumors, there was evidence of allelic imbalance, which is indicative of gene amplification. Allelic imbalance was observed more frequently in invasive tumors (11 of 29 tumors; 38%) than in their noninvasive counterparts (4 of 31 tumors; 13%; P = 0.02). Forty-six of the tumors informative for the polymorphism were available for immunohistochemical analysis. Cyclin D1 expression (nuclear and/or cytoplasmic) was detected in 25 of 46 (54%) tumors. Of these cases, expression of nuclear cyclin D1 was detected in 9 of 46 (20%) tumors, whereas 16 of 46 (35%) tumors showed cyclin D1 staining exclusively confined to the cytoplasm. Neither nuclear staining nor cytoplasmic staining was observed in any of the normal pituitaries or in the negative control. Expression of cyclin D1 was observed in significantly more nonfunctional tumors (18 of 27 tumors; 67%) than in somatotrophinomas (7 of 19 tumors; 37%; P = 0.046). Nuclear cyclin D1 expression was observed more frequently in nonfunctional tumors (8 of 27 tumors; 30%) than in somatotrophinomas (1 of 19 tumors; 5%; P = 0.04). There was no correlation between cyclin D1 expression and tumor grade or between allelic imbalance of CCND1 and cyclin D1 expression. We conclude that amplification of CCND1 occurs in pituitary tumors and that the overexpression of cyclin D1 may be an early event in tumorigenesis. Cyclin D1 overexpression occurring in the absence of CCND1 allelic imbalance suggests that additional mechanisms responsible for deregulated cyclin D1 expression are involved in human pituitary tumorigenesis.

This article has been cited by other articles:

				M. S. Elston, A. J. Gill, J. V. Conaglen, A. Clarkson, R. J. Cook, N. S. Little, B. G. Robinson, R. J. Clifton-Bligh, and K. L. McDonald Nuclear Accumulation of E-Cadherin Correlates with Loss of Cytoplasmic Membrane Staining and Invasion in Pituitary Adenomas J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1436 - 1442. [Abstract] [Full Text] [PDF]

				I. De Martino, R. Visone, A. Wierinckx, D. Palmieri, A. Ferraro, P. Cappabianca, G. Chiappetta, F. Forzati, G. Lombardi, A. Colao, et al. HMGA Proteins Up-regulate CCNB2 Gene in Mouse and Human Pituitary Adenomas Cancer Res., March 1, 2009; 69(5): 1844 - 1850. [Abstract] [Full Text] [PDF]

				P. Aggarwal, M. D. Lessie, D. I. Lin, L. Pontano, A. B. Gladden, B. Nuskey, A. Goradia, M. A. Wasik, A. J.P. Klein-Szanto, A. K. Rustgi, et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication Genes & Dev., November 15, 2007; 21(22): 2908 - 2922. [Abstract] [Full Text] [PDF]

				A. P. Heaney Pituitary tumour pathogenesis. Br. Med. Bull., January 1, 2006; 75-76: 81 - 97. [Abstract] [Full Text] [PDF]

				M Musat, M Korbonits, B Kola, N Borboli, M R Hanson, A M Nanzer, J Grigson, S Jordan, D G Morris, M Gueorguiev, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 423 - 433. [Abstract] [Full Text] [PDF]

				A. Bahar, D. J. Simpson, S. J. Cutty, J. E. Bicknell, P. R. Hoban, S. Holley, M. Mourtada-Maarabouni, G. T. Williams, R. N. Clayton, and W. E. Farrell Isolation and Characterization of a Novel Pituitary Tumor Apoptosis Gene Mol. Endocrinol., July 1, 2004; 18(7): 1827 - 1839. [Abstract] [Full Text] [PDF]

				A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF]

				D.J. Simpson, A.A. Fryer, A.B. Grossman, J.A.H. Wass, M. Pfeifer, J.M. Kros, R.N. Clayton, and W.E. Farrell Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas Carcinogenesis, November 1, 2001; 22(11): 1801 - 1807. [Abstract] [Full Text] [PDF]

				D. J. Simpson, S. J. Frost, J. E. Bicknell, J. C. Broome, A. M. McNicol, R. N. Clayton, and W. E. Farrell Aberrant expression of G1/S regulators is a frequent event in sporadic pituitary adenomas Carcinogenesis, August 1, 2001; 22(8): 1149 - 1154. [Abstract] [Full Text] [PDF]